Annual Accounts Receivable
$745.00 K
+$448.00 K+150.84%
31 December 2023
Summary:
Lineage Cell Therapeutics annual accounts receivable is currently $745.00 thousand, with the most recent change of +$448.00 thousand (+150.84%) on 31 December 2023. During the last 3 years, it has risen by +$741.00 thousand (+18525.00%). LCTX annual accounts receivable is now -98.53% below its all-time high of $50.84 million, reached on 31 December 2021.LCTX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$405.00 K
+$170.00 K+72.34%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly accounts receivable is currently $405.00 thousand, with the most recent change of +$170.00 thousand (+72.34%) on 30 September 2024. Over the past year, it has dropped by -$27.00 thousand (-6.25%). LCTX quarterly accounts receivable is now -99.20% below its all-time high of $50.84 million, reached on 31 December 2021.LCTX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +150.8% | -6.3% |
| 3 y3 years | +10000.0% | +412.7% |
| 5 y5 years | -2.9% | +158.0% |
LCTX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -98.5% | >+9999.0% | -99.2% | +426.0% |
| 5 y | 5 years | -98.5% | >+9999.0% | -99.2% | >+9999.0% |
| alltime | all time | -98.5% | >+9999.0% | -99.2% | >+9999.0% |
Lineage Cell Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $405.00 K(+72.3%) |
| June 2024 | - | $235.00 K(+205.2%) |
| Mar 2024 | - | $77.00 K(-89.7%) |
| Dec 2023 | $745.00 K(+150.8%) | $745.00 K(+72.5%) |
| Sept 2023 | - | $432.00 K(-2.5%) |
| June 2023 | - | $443.00 K(+118.2%) |
| Mar 2023 | - | $203.00 K(-31.6%) |
| Dec 2022 | $297.00 K(-99.4%) | $297.00 K(-31.6%) |
| Sept 2022 | - | $434.00 K(-38.6%) |
| June 2022 | - | $707.00 K(+37.3%) |
| Mar 2022 | - | $515.00 K(-99.0%) |
| Dec 2021 | $50.84 M(>+9900.0%) | $50.84 M(>+9900.0%) |
| Sept 2021 | - | $79.00 K(-75.8%) |
| June 2021 | - | $326.00 K(+199.1%) |
| Mar 2021 | - | $109.00 K(+2625.0%) |
| Dec 2020 | $4000.00(-98.7%) | $4000.00(-98.6%) |
| Sept 2020 | - | $276.00 K(+43.0%) |
| June 2020 | - | $193.00 K(-23.7%) |
| Mar 2020 | - | $253.00 K(-20.2%) |
| Dec 2019 | $317.00 K(-58.7%) | $317.00 K(+101.9%) |
| Sept 2019 | - | $157.00 K(-90.6%) |
| June 2019 | - | $1.67 M(+19.2%) |
| Mar 2019 | - | $1.40 M(+82.8%) |
| Dec 2018 | $767.00 K(-1.7%) | $767.00 K(+6.4%) |
| Sept 2018 | - | $721.00 K(-57.4%) |
| June 2018 | - | $1.69 M(+84.8%) |
| Mar 2018 | - | $916.00 K(+17.4%) |
| Dec 2017 | $780.00 K | $780.00 K(-45.1%) |
| Sept 2017 | - | $1.42 M(+294.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2017 | - | $360.00 K(+74.8%) |
| Mar 2017 | - | $206.00 K(-53.8%) |
| Dec 2016 | $446.00 K(-58.6%) | $446.00 K(-72.2%) |
| Sept 2016 | - | $1.60 M(+104.9%) |
| June 2016 | - | $783.00 K(-30.4%) |
| Mar 2016 | - | $1.13 M(+4.4%) |
| Dec 2015 | $1.08 M(+3.5%) | $1.08 M(+14.2%) |
| Sept 2015 | - | $944.00 K(-3.6%) |
| June 2015 | - | $979.00 K(+13.0%) |
| Mar 2015 | - | $866.20 K(-16.9%) |
| Dec 2014 | $1.04 M(-6.6%) | $1.04 M(+2.7%) |
| Sept 2014 | - | $1.01 M(-14.8%) |
| June 2014 | - | $1.19 M(+45.5%) |
| Mar 2014 | - | $818.30 K(-26.6%) |
| Dec 2013 | $1.12 M | $1.12 M(+727.3%) |
| Sept 2009 | - | $134.80 K(+2708.3%) |
| Sept 2008 | - | $4800.00(+17.1%) |
| June 2008 | - | $4100.00(-59.4%) |
| Mar 2008 | - | $10.10 K(+106.1%) |
| Sept 2007 | - | $4900.00(-16.9%) |
| June 2007 | - | $5900.00(+37.2%) |
| Mar 2007 | - | $4300.00(-45.6%) |
| Sept 2006 | - | $7900.00(+19.7%) |
| June 2006 | - | $6600.00(-98.7%) |
| Mar 2006 | - | $505.50 K(+97.5%) |
| Sept 2005 | - | $256.00 K(+4313.8%) |
| Sept 2004 | - | $5800.00(-98.1%) |
| June 2004 | - | $301.20 K(>+9900.0%) |
| June 2003 | - | $2700.00(-99.5%) |
| Mar 2003 | - | $510.60 K |
FAQ
- What is Lineage Cell Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual accounts receivable year-on-year change?
- What is Lineage Cell Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly accounts receivable year-on-year change?
What is Lineage Cell Therapeutics annual accounts receivable?
The current annual accounts receivable of LCTX is $745.00 K
What is the all time high annual accounts receivable for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual accounts receivable is $50.84 M
What is Lineage Cell Therapeutics annual accounts receivable year-on-year change?
Over the past year, LCTX annual accounts receivable has changed by +$448.00 K (+150.84%)
What is Lineage Cell Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of LCTX is $405.00 K
What is the all time high quarterly accounts receivable for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly accounts receivable is $50.84 M
What is Lineage Cell Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, LCTX quarterly accounts receivable has changed by -$27.00 K (-6.25%)